Search

Your search keyword '"Karla Rodriguez-Lopez"' showing total 4 results
Start Over Author "Karla Rodriguez-Lopez" Publisher elsevier bv
4 results on '"Karla Rodriguez-Lopez"'

1. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

Author

Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso-Gordoa, Masatoshi Eto, Thomas Hutson, Robert Motzer, Eric Winquist, Pablo Maroto, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frederic Rolland, Mototsugu Oya, Karla Rodriguez-Lopez, Kenichi Saito, Jodi McKenzie, and Camillo Porta

Subjects
Oncology, Urology, Radiology, Nuclear Medicine and imaging, Surgery
Published
2023

2. 660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update

Author

Tomas Buchler, Pablo Maroto, Sun Young Rha, Thomas Powles, Toni K. Choueiri, Viktor Grünwald, M.J. Méndez-Vidal, Karla Rodriguez-Lopez, S-H. Hong, Camillo Porta, Eric Winquist, Thomas E. Hutson, Masatoshi Eto, Robert J. Motzer, Evgeny Kopyltsov, Jeffrey C. Goh, Alan D. Smith, T. Takagi, and Dongyuan Xing

Subjects
Oncology, medicine.medical_specialty, Renal cell carcinoma, business.industry, Internal medicine, Toxicity, medicine, Hematology, medicine.disease, business
Published
2021

3. 717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)

Author

Brian I. Rini, Rodolfo F. Perini, Elizabeth R. Plimack, Rachel Kloss Silverman, Karla Rodriguez-Lopez, Thomas Powles, Howard Gurney, Martin H. Voss, and Toni K. Choueiri

Subjects
Oncology, medicine.medical_specialty, business.industry, First line, Hematology, Pembrolizumab, medicine.disease, chemistry.chemical_compound, Clear cell renal cell carcinoma, chemistry, Internal medicine, Medicine, Open label, business, Lenvatinib
Published
2021

4. 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

Author

David F. McDermott, Frede Donskov, Michael B. Atkins, Jahangeer Malik, Scott S. Tykodi, M.A. Climent Duran, J-L. Lee, Teresa Alonso-Gordoa, M.D. Kochenderfer, Niels Viggo Jensen, Rustem Gafanov, J. Burgents, Poul F. Geertsen, Karla Rodriguez-Lopez, H. Liu, J.M.G. Larkin, G. A. Bjarnason, Daniel C. Cho, Alexandr Poprach, and C. Di Simone

Subjects
Oncology, 0303 health sciences, medicine.medical_specialty, business.industry, Hematology, Pembrolizumab, medicine.disease, 03 medical and health sciences, Clear cell renal cell carcinoma, 0302 clinical medicine, First line therapy, 030220 oncology & carcinogenesis, Internal medicine, Cohort, Medicine, business, 030304 developmental biology
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results